AptarGroup NYSE: ATR used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and early 2026 results.
ATR tops Q1 earnings estimates on strong sales growth, but profit declines, pharma headwinds and margin pressure send shares down despite an upbeat Q2 outlook.
AptarGroup, Inc. (ATR) Q1 2026 Earnings Call Transcript
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Stephan Tanda CEO | XMUN Exchange | US0383361039 ISIN |
| US Country | 13,000 Employees | 6 May 2026 Last Dividend | 10 May 2007 Last Split | 21 Apr 1993 IPO Date |
AptarGroup, Inc. is at the forefront of designing and manufacturing innovative solutions for drug delivery, consumer product dispensing, and active material science. With a diverse portfolio aimed at meeting the needs of various markets such as pharmaceuticals, beauty, personal care, home care, and food and beverage, AptarGroup emphasizes its commitment to addressing consumer demands and industry challenges. Operating through three primary segments - Aptar Pharma, Aptar Beauty, and Aptar Closures, the company showcases a multifaceted approach to delivering excellence and innovation. Since its incorporation in 1992, AptarGroup has established a significant global presence, actively serving customers across Asia, Europe, Latin America, and North America from its headquarters in Crystal Lake, Illinois. This extensive footprint underscores its dedication to accessibility and service excellence worldwide.
The comprehensive range of products and services offered by AptarGroup caters to a wide array of market needs, ensuring high-quality, innovative solutions that enhance user experience and functionality. Here's a closer look at their offerings: